Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review)
International Journal of Oncology · 19.12.2023 · 64 (2)
DOI: 10.3892/ijo.2023.5605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 19.12.2023. Verfasst von Chiyun Shao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210022, P.R. Chin…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, RNA Methylation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
RNA methylation modifications are closely linked to tumor development, migration, invasion and responses to various therapies. Recent studies have shown notable advancements regarding the roles of RNA methylation in tumor immunotherapy, the tumor microenvironment and metabolic reprogramming. However, research on the association between tumor chemoresistance and N6‑methyladenosine (m6A) methyltransferases in specific cancer types is still scarce. Colorectal cancer (CRC) is among the most common gastrointestinal cancers worldwide. Conventional chemotherapy remains the predominant treatment modality for CRC and chemotherapy resistance is the primary cause of treatment failure. The expression levels of m6A methyltransferases, including methyltransferase‑like 3 (METTL3), METTL14 and METTL16, in CRC tissue samples are associated with patients' clinical outcomes and chemotherapy efficacy. Natural pharmaceutical ingredients, such as quercetin, have the potential to act as METTL3 inhibitors to combat chemotherapy resistance in patients with CRC. The present review discussed the various roles of different types of key RNA methylation enzymes in the development of CRC, focusing on the mechanisms associated with chemotherapy resistance. The progress in the development of certain inhibitors is also listed. The potential of using natural remedies to develop antitumor medications that target m6A methylation is also outlined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210022, P.R. China.
- School of Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China.
Zitieren
APA
Shao, C., Han, Y., Huang, Y., Zhang, Z., Gong, T., Zhang, Y., Tian, X., Fang, M., Han, X., & Li, M. (2023). Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). International Journal of Oncology, 64(2). https://doi.org/10.3892/ijo.2023.5605
Vancouver
Shao C, Han Y, Huang Y, Zhang Z, Gong T, Zhang Y, et al. Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). International Journal of Oncology. 2023;64(2). doi:10.3892/ijo.2023.5605
BibTeX
@article{Shao2023,
author = {Shao, Chiyun and Han, Yanjie and Huang, Yuying and Zhang, Zhe and Gong, Tao and Zhang, Yajie and Tian, Xiaokang and Fang, Mingzhi and Han, Xuan and Li, Min},
title = {Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review)},
journal = {International Journal of Oncology},
year = {2023},
volume = {64},
number = {2},
doi = {10.3892/ijo.2023.5605}
}
EUVIMED